Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EG12014 vs Herceptin in HER2-Positive Early Breast Cancer
NCT03433313Phase 3Completed
- Sponsor
- EirGenix
- Start
- Oct 2018
- Primary completion
- Jan 2022
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 3 trial of trastuzumab biosimilar EG12014 in breast cancer, sponsored by EirGenix. Started Oct 2018; status: completed.
02
Drugs
trastuzumab biosimilar EG12014
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03433313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03433313.